Ignite Creation Date:
2025-12-24 @ 4:02 PM
Ignite Modification Date:
2025-12-27 @ 4:11 AM
Study NCT ID:
NCT01125566
Status:
COMPLETED
Last Update Posted:
2019-07-18
First Post:
2010-05-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-06-22
Start Date Type:
ACTUAL
Primary Completion Date:
2013-06-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-07-06
Completion Date Type:
ACTUAL
First Submit Date:
2010-05-10
First Submit QC Date:
None
Study First Post Date:
2010-05-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-06-06
Results First Submit QC Date:
None
Results First Post Date:
2014-08-21
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-07-04
Last Update Post Date:
2019-07-18
Last Update Post Date Type:
ACTUAL